

JVCKENWOOD



April 27, 2023

Company	JVCKENWOOD Corporation
Representative	Representative Director of the Board President and CEO EGUCHI Shoichiro (Code: 6632; Prime Market of the Tokyo Stock Exchange)
Contact	General Manager, Corporate Communication Department ENDO Isamu (Tel: +81-45-444-5232)

Transfer of New Healthcare Business

JVCKENWOOD Corporation (“JVCKENWOOD”) has begun discussions with Sysmex Corporation (“Sysmex”) regarding the transfer to Sysmex of JVCKENWOOD’s new healthcare business, as well as its shareholding in Creative Nanosystems Corporation (“CNS”), which was jointly established by JVCKENWOOD and Sysmex for the development and manufacturing of biodevices.

1. Background of the business transfer

In its “VISION 2025” announced today, JVCKENWOOD redefined its business portfolio based on growth potential and capital efficiency, and positions its healthcare business as an area to be restructured and is currently proceeding with such reform.

In this reform, JVCKENWOOD has concluded that Sysmex is the most suitable acquirer of the new healthcare business, including biodevices for specimen testing and exosome* analysis systems, in which both companies have been collaborating to maximize the synergy of their technologies.

JVCKENWOOD expects that this business transfer will enhance the value of diagnostics and contribute to the advancement of medical care in the new healthcare business that it has developed.

*A vesicular granule, about 50-100 nm in diameter, secreted by many types of cells and found in body fluids such as blood, saliva, urine, etc.

2. Impact on performance

The method of transfer is still under consideration, and details will be announced as progress is made with the transaction. Currently, the impact on the consolidated earnings forecast for the fiscal year ending March 31, 2024 (April 1, 2023 to March 31, 2024) announced on April 27, 2023 is immaterial.